Pharmaceuticals company Lupin announced Q1FY25 results: Gross Profit was Rs 37,697 million compared to Rs 33,213 million in Q4FY24, with gross margin of 68.4%. Personnel cost was 17.6% of sales at Rs 9,710 million compared to Rs 9,002 million in Q4FY24. Manufacturing and other expenses were at 29.0% of sales at Rs 15,985 million compared to Rs 14,901 million in Q4FY24. PBT was 18% at Rs 9,930 million on account of better performance of Q1FY25 and an impairment charge of Rs 2,013 million in Q4FY24. Investment in R&D; for the quarter was Rs 3,500 million (6.3% of sales). Operating working capital was Rs 61,686 million. Capital Expenditure for the quarter was Rs 1,117 million. Net Debt as on June 30, 2024 stands at Rs (195) million. Net Debt-Equity as on June 30,2024 stands at 0.00. Commenting on the results, Nilesh Gupta, Managing Director, Lupin Limited said, “We have had a strong quarter on the back of the momentum we built through FY24, with performance driven by new products, key geographies, and improvement in our operating margin and profitability. We are on track for strong, sustainable growth and margin improvement backed by growth in sales, commercial and operating efficiencies, and a strong compliance story.” Result PDF